<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405054</url>
  </required_header>
  <id_info>
    <org_study_id>0457-008</org_study_id>
    <secondary_id>MK0457-008</secondary_id>
    <secondary_id>2006_551</secondary_id>
    <nct_id>NCT00405054</nct_id>
  </id_info>
  <brief_title>A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)</brief_title>
  <official_title>A Phase II Study of MK0457 in Patients With T315I Mutant Chronic Myelogenous Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This study will evaluate MK0457 in patients with chronic myelogenous leukemia and
      Philadelphia chromosome-positive acute lymphoblastic leukemia. Efficacy and safety will be
      evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy</measure>
    <time_frame>24 Months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>continuous infusion every 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0457</intervention_name>
    <description>IV infusion 32 mg/m2/hour; 5-day continuous infusion every 14 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  This study will evaluate MK0457 in patients with CML (chronic myelogenous leukemia)
             and Ph+ALL (Philadelphia chromosome-positive acute lymphoblastic leukemia)

          -  Patients must have adequate organ function

          -  Patients must have documented T315I mutation

        Exclusion Criteria:

          -  Patients within 3 months of allogeneic bone marrow transplant or not fully recovered
             from previous anti-leukemia therapy

          -  Patients with uncontrolled congestive heart failure

          -  Patients with active or uncontrolled infection or active Hepatitis B or C

          -  Patients with known HIV positivity or AIDS related illness

          -  Patients with currently active second malignancy, other than non-melanoma skin cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Colombia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Seymour JF, Kim DW, Rubin E, Haregewoin A, Clark J, Watson P, Hughes T, Dufva I, Jimenez JL, Mahon FX, Rousselot P, Cortes J, Martinelli G, Papayannidis C, Nagler A, Giles FJ. A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer J. 2014 Aug 15;4:e238. doi: 10.1038/bcj.2014.60.</citation>
    <PMID>25127392</PMID>
  </results_reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2006</study_first_submitted>
  <study_first_submitted_qc>November 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2006</study_first_posted>
  <last_update_submitted>January 23, 2015</last_update_submitted>
  <last_update_submitted_qc>January 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

